Hormone Replacement Therapy Market -
Trends, and Forecast to 2026
New mergers and acquisitions is one of the major factor driving the growth of the hormone
replacement therapy market. For instance, in 2014, Pfizer Inc., a U.S.-based pharmaceutical
company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting
growth hormone (hGH-CTP) and innovative treatments for growth hormone deficient patients.
hGH-CTP is more convenient, as the patients need to take just one injection in a week rather
than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults
and children with growth hormone deficiency.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2079
Robust pipeline is also expected to support growth of the hormone replacement therapy market
size. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company,
completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth
hormone deficiency in adults.
The global hormone replacement therapy market size was valued at US$ 10.58 billion in 2017
and is expected to witness a CAGR of 5.2% over the forecast period (2018 – 2026).
Market Dynamics
Increasing number of people suffering from hypogonadism and rising adoption of testosterone
products in various economies is expected to propel overall growth of the market. According to
the data published in the European Association of Urology Journal: 2017, testosterone
prescription trends in the U.S. exhibited an increase between 1.8- and 4-fold over the last two
decades (1997 - 2017). Moreover, from 2000 to 2011, there was a 4.3-fold increase in
testosterone testing when compared to a 3.7-fold increase in prescriptions.
Rising number of generic versions of hormone replacement therapies by various manufacturers
will drive growth of the market in terms of volume and value. For instance, Teva
Pharmaceutical Industries Ltd. launched the generic Axiron1 (testosterone) topical solution CIII,
30 mg/1.5 mL, in the U.S. on August 18, 2017 to treat adult males who have low or no